摘要
目的分析高血压合并冠心病应用氨氯地平阿托伐他汀钙片治疗的疗效。方法90例高血压合并冠心病患者,经随机数字表法分成对照组与观察组,各45例。对照组给予苯磺酸氨氯地平片治疗,观察组给予氨氯地平阿托伐他汀钙片治疗。对比两组血压指标(收缩压、舒张压)、心功能指标[血清心肌肌钙蛋白T(cTnT)、孤独G蛋白偶联受体配体(Apelin)、左心室射血分数、每搏输出量]、血脂指标(甘油三酯、总胆固醇)及不良反应发生情况。结果治疗后,两组收缩压、舒张压水平均低于治疗前,且观察组收缩压(120.25±4.13)mm Hg(1 mm Hg=0.133 kPa)、舒张压(82.15±4.26)mm Hg均较对照组的(131.58±3.68)、(88.26±5.31)mm Hg低(P<0.05)。治疗后,两组cTnT、Apelin均低于治疗前,左心室射血分数、每搏输出量均高于治疗前,且观察组cTnT(0.03±0.01)μg/L、Apelin(1.42±0.13)μg/L均较对照组的(0.05±0.01)、(1.70±0.14)μg/L低,左心室射血分数(47.62±4.15)%、每搏输出量(55.24±3.18)ml均较对照组的(43.26±3.38)%、(52.15±2.46)ml高(P<0.05)。治疗后,两组甘油三酯、总胆固醇均低于治疗前,且观察组甘油三酯、总胆固醇分别为(1.68±0.25)、(3.26±0.24)mmol/L,均低于对照组的(2.12±0.42)、(4.05±0.21)mmol/L(P<0.05)。观察组不良反应发生率为6.67%,对照组为4.44%;两组不良反应发生率相近(χ^(2)=0.212,P=0.645>0.05)。结论氨氯地平阿托伐他汀钙片对高血压合并冠心病有效,相比氨氯地平更有助于改善血压及心功能,且安全性良好。
Objective To analyze the curative effect of amlodipine besylate and atorvastatin calcium tablets on patients with hypertension complicated with coronary heart disease.Methods 90 patients with hypertension complicated with coronary heart disease were divided into a control group and an observation group by random numerical table,with 45 cases in each group.The control group was treated with amlodipine besylate tablets,and the observation group was treated with amlodipine besylate and atorvastatin calcium tablets.Comparison of blood pressure index(systolic blood pressure,diastolic blood pressure),cardiac function index[serum cardiac troponin T(cTnT),solitary G protein-coupled receptor ligand(Apelin),left ventricular ejection fraction,stroke output],blood lipid indicators(triglyceride,total cholesterol),and the occurrence of adverse reactions between the two groups.Results After treatment,the levels of systolic and diastolic blood pressure in both groups were lower than those before treatment;in the observation group,the systolic blood pressure was(120.25±4.13)mm Hg(1 mm Hg=0.133 kPa)and the diastolic blood pressure was(82.15±4.26)mm Hg,which were lower than(131.58±3.68)and(88.26±5.31)mm Hg in the control group(P<0.05).After treatment,cTnT and Apelin in both groups were lower than those before treatment,and the left ventricular ejection fraction and stroke output were higher than those before treatment;the observation group had cTnT of(0.03±0.01)μg/L and Apelin of(1.42±0.13)μg/L,which were lower than(0.05±0.01)and(1.70±0.14)μg/L in the control group;the observation group had left ventricular ejection fraction of(47.62±4.15)%and stroke volume of(55.24±3.18)ml,which were higher than(43.26±3.38)%and(52.15±2.46)ml in the control group(P<0.05).After treatment,the triglyceride and total cholesterol in both groups were lower than those before treatment;the triglyceride and total cholesterol were(1.68±0.25)and(3.26±0.24)mmol/L in the observation group,which were lower than(2.12±0.42)and(4.05±0.21)mmol/L in the control group(P<0.05).The incidence of adverse reactions was 6.67%in the observation group and 4.44%in the control group;the incidence of adverse reactions in the two groups was similar(χ^(2)=0.212,P=0.645>0.05).Conclusion Amlodipine besylate and atorvastatin calcium tablets are effective for hypertension complicated with coronary heart disease,and is more helpful to improve blood pressure and cardiac function compared to amlodipine,and has good safety.
作者
黄崇峰
HUANG Chong-feng(Zhangtun Hospital of Hualou Town,Dezhou 253612,China)
出处
《中国现代药物应用》
2025年第11期105-108,共4页
Chinese Journal of Modern Drug Application
关键词
高血压
冠心病
氨氯地平阿托伐他汀钙片
血压
心功能
Hypertension
Coronary heart disease
Amlodipine besylate and atorvastatin calcium tablets
Blood pressure
Cardiac function
